PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31954752-9	2020	In particular, the focus was on metformin action on RAS/RAF/MAPK pathway.	Metformin	32-41	zinc fingers and homeoboxes 2	Homo sapiens	56-59	
23695170-8	2013	However, further studies are required to investigate better the effect of metformin action on the RAS/RAF/MAPK pathway and the best context in which to use metformin in combination with molecular targeted agents.	Metformin	74-83	zinc fingers and homeoboxes 2	Homo sapiens	102-105	
26673006-4	2016	EXPERIMENTAL DESIGN: Since single agent metformin enhances proliferating signals through the RAS/RAF/MAPK pathway, and several MEK inhibitors (MEK-I) demonstrated clinical efficacy in combination with other agents in NSCLC, we tested the effects of metformin plus MEK-I (selumetinib or pimasertib) on proliferation, invasiveness, migration abilities in vitro and in vivo in LKB1 positive NSCLC models harboring KRAS wild type and mutated gene.	Metformin	40-49	zinc fingers and homeoboxes 2	Homo sapiens	97-100	
26052399-6	2015	Metformin (through 5"-adenosine monophosphate-activated protein kinase pathway activation) and statins (through 3-hydroxy-3-methylglutaryl coenzyme A inhibition) show anti-tumoral properties modifying several steps of RAS/RAF/MEK/ERK, PI3K/AKT/mTOR and Wnt/beta-catenin signaling cascades.	Metformin	0-9	zinc fingers and homeoboxes 2	Homo sapiens	222-225	
23937224-4	2013	EXPERT OPINION: Future perspective studies are required in nonsmall-cell lung cancer (NSCLC) patients to better investigate the effect of metformin action on the RAS/RAF/MAPK pathway and the best context in which to use metformin in combination with molecularly targeted agents.	Metformin	138-147	zinc fingers and homeoboxes 2	Homo sapiens	166-169	
23707609-10	2013	These results highlight the Raf-ERK-Nrf2 axis as a new molecular target in anticancer therapy in response to metformin treatment.	Metformin	109-118	zinc fingers and homeoboxes 2	Homo sapiens	28-31	
24209692-4	2013	We identified multiple rare variants in KSR2 that disrupt signaling through the Raf-MEKERK pathway and impair cellular fatty acid oxidation and glucose oxidation in transfected cells; effects that can be ameliorated by the commonly prescribed antidiabetic drug, metformin.	Metformin	262-271	zinc fingers and homeoboxes 2	Homo sapiens	80-83	
23707609-0	2013	Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways.	Metformin	0-9	zinc fingers and homeoboxes 2	Homo sapiens	87-90	
23707609-7	2013	We also found that metformin regulation of Nrf2 expression is mediated by a Keap1-independent mechanism and that metformin significantly attenuated Raf-ERK signaling to suppress Nrf2 expression in cancer cells.	Metformin	113-122	zinc fingers and homeoboxes 2	Homo sapiens	148-151